Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic strengthens pacemaker line:

This article was originally published in Clinica

Executive Summary

Medtronic has entered into a non-exclusive sublicence with wireless data communication technology company LifeSync Corporation to gain its patent portfolio. The sublicence will allow Medtronic to use LifeSync's wireless ECG data communication system in connection with implantable devices for cardiac pacing, defibrillation, neurostimulation, gastrostimulation and urological stimulation. Fort Lauderdale, Florida-based LifeSync said that it grants sublicences for its intellectual property to third parties for uses that it does not intend to internally develop and commercialise, in a statement made on August 15. This is the second deal Medtronic has struck up in a week to boost, in particular, its range of pacemakers. The company bought MRI safety patents from Biophan on August 9 (see Clinica No 1269, p 10).

You may also be interested in...



Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Topics

UsernamePublicRestriction

Register

MT049468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel